Lunai Bioworks Inc.
LNAI - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$760.64K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $760,635.00 |
|---|---|
| Enterprise Value | $-374,466,117.00 |
| Earnings per Share | $-1.06 |
| Beta | 0.35 |
| Outstanding Shares | 4,615,503 |
Return
| Return on Equity | 39.47% |
|---|---|
| Return on Assets | -0.04% |
| Return on Invested Capital | 0.03% |
Valuation & Multiples
| P/E Ratio | -0.2 |
|---|---|
| PEG | 0.21 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | -6344.09 |
| Enterprise Value to EBIT | 134.73 |
| Enterprise Value to Net Income | 105 |
| Total Debt to Enterprise | -4.06 |
| Debt to Equity | -148.3 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 13, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Lunai Bioworks Inc.
29 employees
CEO: David Weinstein
A company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.